

DAFTAR PUSTAKA

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al 2016 ESC Guideline for The Diagnosis and Treatment of Acute and Chronic Heart Failure. *European Heart Journal*. 2016;18(8):891–975.
2. Tanase DM, Radu S, Al Shurbaji S, Baroi GL, Costea CF, Turliuc MD, et al. Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications. *Int. J. Mol. Sci*. 2019;20(11):1–23.
3. Paulus WJ, Tschop C. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation. *Journal of the American College of Cardiology*. 2013;62(4):263–72.
4. Toma M, Mak GJ, Chen V, Hollander Z, Shannon CP, Lam KKY. Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. *ESC Heart Failure*. 2017;4(3):301–11.
5. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *J Am Coll Cardiol*. 2012;59(11):998–1005.
6. Upadhyay B, Pisani B, Kitzman DW. Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. *J Am Geriatr Soc*. 2017;65(11):2431–40.
7. Meijers WC, van der Velde AR, de Boer RA. Biomarkers in heart failure with preserved with ejection fraction. *Neth Heart J*. 2016;24(4):252–8.
8. Plitt GD, Spring JT, Moulton MJ, Agrwal DK. Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction. *Expert Rev Cardiovasc Ther*. 2018;16(8):579–89.
9. Nagueh SF, Smiseth OA, Appleton CP. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc*

Imaging. 2016;17:277–314.

10. Vasan RS, Levy D. Defining Diastolic Heart Failure – A Call for Standardized Diagnostic Criteria. *Circ.* 2000;101(17):2118–21.
11. Wu JY, Chung S. Evaluation of Diastolic Function by Three-Dimensional Volume Tracking of the Mitral Annulus With Cardiovascular Magnetic Resonance: Comparison With Tissue Doppler Imaging. *J Cardiovasc Magn Reson.* 2014;16(1):1–14.
12. Yancy CW, Jessup M, Bozkurt B. 2017 ACCF/AHA focused update of the 2013 ACC/AHA guideline for the management of heart failure: a Report of The American College of Cardiology/American Heart Association Task Force on Clinical Practice Guideline. *Circulation.* 2017;136(6):137–61.
13. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The Role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. *European Heart Journal.* 2005;26(21):2277–84.
14. Brunner-La rocca, H.P, Sanders-van wijk, S. Natriuretic Peptides in Chronic Heart Failure. *Card. Fail. Rev.* 2019;5(1):44–9.
15. Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions. *Heart.* 2018;104(5):377–84.
16. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: Findings from the I-PRESERVE trial. *Circ. Heart Fail.* 2011;4(5):569–77.
17. Lam CSP, Voors AA, de Boer RA, Solomon SD. Heart failure with preserved ejection fraction: from mechanism to therapies. *European Heart Journal.* 2018;39(30):2780–92.
18. Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, et al. Right ventricular dysfunction and failure in heart failure with preserved ejection fraction HFPEF: mechanisms and management. Position statement on behalf of the European Society of Cardiology. *Eur J*

- Heart Fail. 2018;20(1):16–37.
19. López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G, et al. Circulating biomarkers of myocardial fibrosis: The need for a reappraisal. *J Am Coll Cardiol*. 2015;65(2):2449–56.
 20. Richard MA. Circulating biomarkers of cardiac fibrosis do we have any and what use are they?. *Circ Heart Fail*. 2017;10(3):1–5.
 21. Gonzales A, Schelbert EB, Diez J, Butler J. Myocardial interstitial fibrosis in heart failure. *Journal of The American of Cardiology*. 2018;71(15): 1696–706.
 22. Zhang T, Shao B, Liu GA. Research on clinical value of galectin-3 in evaluating the prognosis of acute heart failure. *Eur Rev Med Pharmacol*. 2017;21(19):4406–10.
 23. Choi HM, Park MS, Youn JC. Update on heart failure management and future directions. *Korean J Intern Med*. 2019;34(1):11–43.
 24. Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, et al. Galectin-3 in patients with heart failure with preserved fraction ejection : results from the Aldo-DHF trial. *European Journal of Heart Failure*. 2015;17(2): 214–23.
 25. Liu T, Song D, Dong J, Zhu P, Liu J, Liu W, et al. Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure. *Physiol*. 2015;8:1–13.
 26. Wu CK, Su MY, Lee JK, Chiang FT, Hwang JJ, Lin JL, et al. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. *Sci. Rep*. 2015; 5(1):1–10.
 27. de Boer RA. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. *Ann Med*. 2011;43(1):60–8.
 28. de Filippi CR, Christenson RH. Evolving role of galectin-3 as a cardiac biomarker. *JACC : Heart Failure*. 2015;3(3):253–6.
 29. Choi HM, Park MS, Youn JC. Update on heart failure management and future directions. *Korean J Intern Med*. 2019;34(1):11–43.
 30. Tawil J, Gelzins TA. Differential diagnosis and clinical management of diastolic heart failure: current best practice. *Research Reports in Clinical*

Cardiology. 2016;7:117–35.

31. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker. Troponin Elevation in Heart Failure Prevalence, Mechanism, and Clinical Implication. *Journal of the American College of Cardiology*. 2010;56(10):1071–8.
32. Saiki H, Petersen IA, Scott CG. Risk of Heart Failure with Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. *Circulation*. 2017;135(15):1388–96.
33. Brower FP, de Boer RA, van der Harst P. Incidence and epidemiology of new onset heart failure with preserved versus reduced ejection fraction in a community-based cohort: 11 year follow up of PREVEND. *Eur Heart J*. 2013;34(19): 1424-31.
34. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol*. 2017;14:591–602.
35. Baldi C, Wilson GA, Wilson LC, Wilkins GT, Lambert RR. The type 2 diabetic heart: Its role in exercise intolerance and the challenge to find effective exercise interventions. *Sport Meds*. 2016;46(11):1605-17.
36. Sygitowics G, Tomaniak M, Filipiak KJ, Kaltowski L, Sitkiewics D. Galectin-3 in Patient with Acute Heart Failure: Preliminary Report on First Polish Experience. *Adv Clin Exp Med*. 2016; 25(4):617–23.
37. Goel S, Miller A, Sharma A, Gidwani U, Shania J. Treatment modalities for heart failure with preserved ejection fraction (HFpEF) – current state of evidence and future perspective. *Clin Exp Cardiol*. 2015,6(7):1–9.
38. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J et al. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure anpreserved left ventricular ejection fraction. *Am J Cardiol*. 2008;102(6): 733–7.
39. Mohammed SF, Hussain S, Mirzoyev SA, et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. *Circulation*. 2015;131(6):550–9.
40. Westermann D, Lindner D, Kasner M. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and

normal ejection fraction. *Circ Heart Fail.* 2011;4(1):44–52.

41. Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. *J. Biol. Eng.* 2018;12(2):1–10.
42. Troughton RW, Richards AM. B-Type Natriuretic Peptides and Echocardiographic Measures of Cardiac Structure and Function. *JACC:Cardiovascular Imaging.* 2009;2(2):216–25.
43. Michalska-Kasiczak M, Bielecka-Dabrowa A, von Haehling S, Anker SD, Rysz J, Banach M. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: An overview. *Arch. Med.Sci.* 2018;14(4):890–909.
44. van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreir AF, Begieneman MP, Bronzwaer JG, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. *Circulation* 2012;126(7):830–9.
45. Suthahar N, Meijers WC, Silljei HW, Ho JE, Liu F, de Boer R. *Theranostics.* 2018;8(3):593–6
46. Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). *International Journal of Molecular Medicine.*2018;41(2):599–614.
47. van der Velde AR, Lexis CPH, Meijers WC, van der Horst IC, Lipsic E, van Veldhuisen DJ, et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. *Clin Chim Acta.*2016;452:50–7.
48. Schinder EI, Szymansky JJ, Hock KG, Geltman EM, Scott MG. Short and Long-term Biologic Variability Of Galectin-3 and Other Cardiac Biomarker in Patients with Stable Heart Failure dan Helthy Adult. *Clinical Chemistry.*2016;62(2):360–6.
49. Tromp J, Teng TH, Tay WT, Heng CL, Narasimhan C, Shimizu W, et al. Heart failure with preserved ejection fraction in Asia on behalf of the ASIAN-HF Investigators. *European Journal of Heart Failure.* 2019;21(1):23–36.

50. Beltrami G, Ruocco G, Dastidar AG, Franci B, Lucani B, Aloia E, et al. Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. *Clinica Chimica Acta*. 2016;457: 99–105.
51. Triposkiadis F, Giamouzis G, Parissis J. Reframing the association and significance of comorbidities in heart failure. *Eur J Heart Fail*. 2016;18:744–58.
52. Lundorff IJ, Sengelov M, Godsk JP. Echocardiographic predictors of mortality in women with heart failure with reduced ejection fraction. *Circ Cardiovasc Imaging*. 2018;11(11):1–9.
53. Beale AL, Meyer P, Marwick TH. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. *Circulation*. 2018;138:198–205.
54. Sanders-van wijk S, van Empel V, Davarzani N. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. *Eur J Heart Fail*. 2015;17:1006–14.
55. Yin QS, Shi B, Dong L, Bi L. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. *Journal of Geriatric Cardiology*. 2014; 11: 79–82.
56. Ansari U, Behnes M, Hoffmann J, Natale M, Fastner C, El-battrawy I, et al. Galectin-3 reflects the echocardiographic grades of left ventricular diastolic dysfunction. *Ann Ab Med*. 2018;38(4):306–15.
57. Cui Y, Qi X, Huang A, Li J, Hou W, Liu K. Differential and predictive value of galectin-3 and soluble suppression of tumorigenicity-2 (sST2) in heart failure with preserved ejection fraction. *Med Sci Monit* 2018;24:5139–46.
58. Kanukurti J, Mohammed N, Sreedevi NN, Khan SA, Baba KS, Bhaskar MV, et al. Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction. *J Lab Physicians*. 2020;12:126–32
59. Gopal DM, Ayalon N, Wang YC, Siwik D, Sverdlov A, Donohue C, et al. Galectin-3 Is Associated With Stage B Metabolic Heart Disease and

- Pulmonary Hypertension in Young Obese Patients .J Am Heart Assoc. 2019;8:1–30.
60. Iqbal N, Wentworth B , Choudhary R , Landa AD , Kipper B , Farid A , et al. Cardiac biomarkers: New tools for heart failure management. *Cardiovasc Diagn Ther.*2012;2(2):147–64.
61. Obokata M, Reddy YN, Melenovsky V, Jarolim P, Bourlag BA. Relationships between novel biomarkers and hemodynamics during exercise in heart failure with preserved ejection fraction. *Journal of cardiac Failure.* 2017;23(8):1–19.
62. Bourlag BA. The pathophysiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol.* 2014;11(9):507–15.
63. Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow G, Gheorghiade M, et al. Prevalence, clinical phenotype, and outcome associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. *Am J Cardiol.* 2012;110(6):870–6.
64. Remmenzwaal S, van Ballegooijen A, Beulens JW. Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction- a systematic review and meta-analysis. *BMC Med.* 2020;290(18):1–20.
65. Shuai XX, Chen YY, Lu YX, Su GH, Wang YH, Zhang HL, et al. Diagnosis of heart failure with preserved ejection fraction: which parameters and diagnostic strategies are more valuable?. *European Journal of Heart Failure.* 2011; 13: 737–45.
66. Polat V, Bozcali E, Uygun T, Opan S, Karakaya O. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. *Acta Cardiol.* 2016;71(2): 191–7.
67. Hamdy RM, Mohamed L , Abdel-Rahman1 T, El-Malah A, Abd-Allah M. Clinical and Echocardiographic Correlation of Galectin-3 in Well Defined Heart Failure Patients . *AAMJ.* 2014;12(4): 1–22.
68. Kukes VG, Gyamdjyan KA, Shikh EV, Marinin VF, Maximov ML, Prokofiev AB. The Utility of Galectin-3 as a Diagnostics and Pharmacotherapy Monitoring Biomarker in Heart Failure.

Cardiology.2019;6(9): 893–902.

69. Labedev DA, Lyasnikova EA, Vasilyeva EY, Babenko AY. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midranged and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis. *Journal of Diabetes Research*. 2020;20(2):1–9.
70. Oikonomou E, Vogiatzi G, Tsalamandris S, Mourouzis K, Siasos G, Lazaros G, et al. Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction. *Biomark Med*. 2018;12(7):783–97.

